Spending-bill provision won't protect biotech firms like critics say

04/9/2013 | Bloomberg

The hysteria over a biotech crop provision signed into law last month has no basis because there's no truth to critics' claims about the law, Bloomberg View columnist Ramesh Ponnuru writes. The law's real impact is modest, and it would permit farmers to continue using products that are safe in case of frivolous lawsuits, Ponnuru writes.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ